Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Peripheral T Cell Lymphoma Clinical Trial

Official title:

An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), Given With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) Therapy for Front Line Treatment in Patients With Peripheral T-cell Lymphoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05239910
• Other study ID #: RP6530+CHOP-2103
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 2023
• Est. completion date: May 2027

Study information

• Verified date: October 2022
• Source: Rhizen Pharmaceuticals SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group 2: 800mg BID) when given with standard regimen of CHOP, followed by single agent maintenance treatment with tenalisib for 1 year. Recruitment of 20 patients each will be done in both groups in parallel. All eligible patients will start with a run-in period, in which single agent tenalisib will be administered for 3 cycles of 21 days each. Post run-in period, all patients will proceed to receive tenalisib and CHOP regimen for next 6 cycles. After completion of 6 cycles of T-CHOP treatment, maintenance therapy with tenalisib will be initiated in patients showing CR and PR. These patients will continue to receive single agent tenalisib for 1 year.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of full informed consent prior to any study-specific procedures.

2. Pathologically confirmed diagnosis of PTCL according to WHO 2016 classification

criteria EXCEPT following subtypes:

• ALK-positive anaplastic T-cell lymphoma; CD30+ PTCL (who are eligible for BV and CHOP combination); extra-nodal NK/T-cell lymphoma, nasal type; HTLV1- associated lymphoma; primary cutaneous anaplastic T-cell lymphoma, T-cell lymphoma with only skin involvement

3. Disease status is defined as treatment naïve patients with PTCL who have not received prior systemic therapy for lymphoma.

4. Must have ECOG performance status = 2

5. Patients must have measurable disease defined as at least one bi-dimensional measurable lesion assessed radiologically with a minimum measurement of > 1.5 cm in the longest diameter.

6. Patients must be fit to receive full-dose CHOP Therapy.

7. Adequate bone marrow, liver and renal functions

Exclusion Criteria:

1. Patients who have received prior systemic therapy for lymphoma or are receiving anticancer therapy including any investigational therapy (e.g., chemotherapy, biologic therapy, hormonal therapy).

2. Patients with known Central Nervous System (CNS) lymphoma or CNS involvement by lymphoma.

3. Active uncontrolled systemic fungal, bacterial or viral infection

4. Patient with ongoing or significant cardiac disease in last 6 months which according to the investigator can impact study participation

5. Patients with co-morbidities/complications

6. Known history of severe liver injury/disease

7. Active viral infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. and history of severe cutaneous reactions

8. Patient with any other active malignancy at the time of screening except for adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,

9. Hypersensitivity to the active substance or to any of the excipients.

10. Pregnancy or lactation.

11. Concurrent medications or substance, the example of these treatment includes strong inhibitors or inducer of CYP3A4 enzyme or substrate of CYP3A4 with narrow therapeutic index.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T Cell Lymphoma

Intervention

Drug:
• Tenalisib
Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.

Locations

Country	Name	City	State
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Rhizen Pharmaceuticals SA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response (CR) rate at the end of T-CHOP treatment.	CR rate is defined as the percentage of patients showing complete response as assessed by the Investigator according to the Lugano Classification.	9 months
Secondary	Overall Response Rate (ORR) at the end of T-CHOP treatment.	ORR is defined as sum of CR and PR rates, as assessed by the Investigator according to the Lugano Classification	9 months
Secondary	Duration of Response (DoR),	The duration of response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.	3 years
Secondary	Progression-Free Survival (PFS)	PFS is defined as the duration of time from start of treatment to time of documentation of progression or death from any cause	3 years
Secondary	Overall Survival (OS)	OS is defined as the duration of time from start of treatment to death from any cause.	3 years